Metformin targets the gut instead of the liver to lower glucose
For decades, physicians and scientists thought metformin, the leading Type 2 diabetes medication taken by millions worldwide, mainly targets the liver to suppress glucose production.
another news portal
For decades, physicians and scientists thought metformin, the leading Type 2 diabetes medication taken by millions worldwide, mainly targets the liver to suppress glucose production.
A study reveals low adherence to UK nutrition targets in major restaurant chains, raising concerns about dietary risks for cardiovascular disease and diabetes.
Mississippi State University biologist Jean-Francois Gout’s contributions to a study highlighting key advances in the complexity of aging now are published in Science Advances, a
Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in
When conversation drifted into fantasy, one man grabbed a hammer and prepared for war.
U.S. immigration officials have quietly lifted a hold on green card and visa applications for doctors from three dozen countries
The condition affects one in 10 women in the UK and can cause debilitating pain and infertility.
This is a MedPage Today story. A western New York health insurance provider for seniors and the CEO of its medical analytics arm have agreed
HHS Secretary Robert F. Kennedy, Jr. has been pushing the narrative that raw unpasteurized milk is both safe and better for your health than pasteurized
The strike further delays Tom Lawson’s gastric bypass surgery after a more than three-year wait.
Resident doctors in England – the new name for junior doctors – are taking part in their 15th walkout in a long-running pay dispute.
The team aims to find out what it is about the Isle of Wight that makes people feel better.
Menopause symptoms like hot flushes can be debilitating. Dr. Katie Barber highlights new treatments, including fezolinetant, for improved patient care.
Research reveals that Medicare Advantage enforcement tools are insufficient, highlighting the need for stronger oversight to protect beneficiaries effectively.